Kangqiao Capital, a private equity fund focusing on the healthcare industry in Asia, and Haisun Biomedical Co., Ltd. (abbreviation: Haisun Biomedical Co., Ltd.) today jointly announced that Haisun Biotech has completed a financing of US$315 million.
Haisen Biology is an innovative biomedical enterprise, jointly invested and established by Kangqiao Capital, Hefei Industrial Investment Group and Feidong County, Hefei City.
The round of financing was jointly led by Cambridge Capital and Abu Dhabi sovereign wealth fund Mubadala Investment Company, and other institutional investors followed suit. Proceeds will be used for future acquisitions and business development of the innovative product pipeline.
Mr. Fu Wei, CEO of Kangqiao Capital, said: 'Hessian Bio is a well-established Chinese biopharmaceutical company with huge growth potential. The company's sales increased by 47% from the second quarter to the fourth quarter of 2022, This is an example of the successful implementation of Cambridge Capital's unique and effective 'investment plus operation' strategy. We believe that attractive investment value, coupled with strong operating and growth momentum, will create long-term benefits for Cambridge Capital and our investors. sustainable value.'
'We look forward to deepening our relationship with Hessian and leveraging the synergy between Hessian and our other portfolio companies to further strengthen C-Bridge Capital's strong world-class healthcare ecosystem,' added Mr. Fu Wei.
Mohamed Albadr, head of the China office of Mubadala Investment Company, said: 'We are very pleased to cooperate with Cambridge Capital and Hessian to jointly build a leading biomedical platform to provide Chinese patients with acute and severe diseases. High-quality, reliable and accessible medical and health products.'
Mr. Xia Shaofei, CEO of Hessian Bio, said: 'The funds raised will promote our growth and expansion plans, making us a leading biopharmaceutical company in the fields of chronic diseases, age-related diseases, and acute and severe diseases in China, and realize the Our development vision. Through organic growth and future acquisitions, we will continue to form effective commercial synergies with our existing product portfolio, and bring more valuable medical and health solutions to patients, while building a health management ecosystem in China lock up.'
The latest funding round follows Hessian's acquisition of exclusive mainland China rights to five cardiovascular and metabolic drugs from Takeda in March 2022. At the same time, Haisen Biological plans to build a strong and innovative biomedical industry base in Hefei, and the late-stage product pipeline will be synergistic with the current commercial platform to further support the company's future development.
About Cambridge Capital
Cambridge Capital is an asset management company focusing on the healthcare industry, committed to continuously creating value and integrating global resources. Kangqiao Capital cooperates with the world's top entrepreneurs and scientists, empowers leading companies in the medical and health industry with its original 'investment plus operation' strategy, improves the accessibility of medical services, promotes innovation, and improves efficiency to solve unmet medical needs in the world . Established in 2014, Cambridge Capital has a global professional team integrating investment, healthcare and portfolio management. Headquartered in Singapore, the company has offices in Shanghai, Beijing, Hong Kong, New York, and offices in Boston, San Diego, San Francisco, Abu Dhabi, Seoul, and Tokyo. Cambridge Capital focuses on platform construction in the three core areas of biomedicine, medical technology and medical services.
About Mubadala Investment Company
Mubadala Investment Company is a sovereign investor that manages a global portfolio to generate sustainable investment returns for the Government of Abu Dhabi. Mubadala's assets under management are currently as high as US$284 billion, covering six continents, involving multiple industries and asset classes. The company leverages its deep industry expertise and long-term partnerships to simultaneously promote sustainable development and profit growth, helping the United Arab Emirates' continued economic diversification and global integration.
About Haisen Biomedical Co., Ltd.
Haisen Biomedicine Co., Ltd. (abbreviation: Haisen Biomedicine) is an innovative biomedical enterprise. Adhering to the core values of integrity, agility, innovation and ownership, Haisen Bio always insists on putting the needs of doctors and patients first, and with diversified methods, its business quickly spreads all over the country. We are committed to becoming a leading innovative medical and health company in China, and we work together with relevant government agencies, medical and health professionals and industry partners to provide high-quality solutions, create a health management ecosystem, and benefit more patients.
About Hefei Industrial Investment Group
The life and health industry is one of the leading industries in the key layout of Hefei City. As the old shareholders of Haisen Biology, Hefei Industrial Investment Group and Feidong County will join hands with the new shareholders to fully support the localization and transfer of all Haisen Biological pipelines. Create a base project for the biomedical industry in Hefei.
About Feidong County
Biomedicine is one of the strategic emerging industries that Feidong focuses on. With the goal of building 'one park, one port, and one base',
Based on the Hefei Haisen Biological Project cooperation, we will further expand the cooperation results, and at the same time aim at the direction of attracting medical equipment and raw material preparation projects, so as to promote the development of the county's biomedical industry into an accelerated mode.
Contact:
Email: Hasten.Communication@hastenpharma.com
CAMBRIDGE CAPITAL HOLDINGS, INC. 
